Steven John Green
Director/Board Member at Biogen Idec Ltd.
Network origin in Steven John Green first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 13 | |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom.
4
| Subsidiary | Biotechnology | 4 |
Silver Acquisition Co. Ltd.
 Silver Acquisition Co. Ltd. BiotechnologyHealth Technology Founded in 2014, Silver Acquisition Co. Ltd. is a biotechnology research and British experimental development company. Part of Biogen, Inc., the company is based in Maidenhead, UK. The company's focus is on developing new biotechnology products through research and experimentation.
1
| Subsidiary | Biotechnology | 1 |
Convergence Pharmaceuticals Holdings Ltd.
 Convergence Pharmaceuticals Holdings Ltd. Financial ConglomeratesFinance Part of Biogen, Inc., Convergence Pharmaceuticals Holdings Ltd. functions as an investment holding British company. The company is based in Maidenhead, UK.
1
| Subsidiary | Financial Conglomerates | 1 |
Amicus Therapeutics International Holding Ltd.
 Amicus Therapeutics International Holding Ltd. Financial ConglomeratesFinance Founded in 2016, Amicus Therapeutics International Holding Ltd. is a British company that functions as an investment holding company. Part of Amicus Therapeutics, Inc., the company is based in Marlow, UK.
1
| Subsidiary | Financial Conglomerates | 1 |
Old Convergence Pharmaceuticals Ltd.
 Old Convergence Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2010, Old Convergence Pharmaceuticals Ltd. is a subsidiary of Biogen, Inc. that develops analgesics for the treatment of chronic pain. The company is based in Maidenhead, UK.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Steven John Green via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Compliance Officer Corporate Officer/Principal | |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
| ALLERGAN, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Tiburio Therapeutics, Inc.
 Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Founder | |
Cydan LLC
 Cydan LLC Medical DistributorsDistribution Services Cydan LLC operates as an orphan drug accelerator that identifies and de-risks programs. The firm's model evaluates programs for treating rare diseases with unmet medical need and is aimed at creating new companies to develop those therapies. The company was founded by James G. McArthur in 2013 and is headquartered in Cambridge, MA. | Medical Distributors | Chairman Founder | |
| SHIRE | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| ELIEM THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal Founder | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Biotechnology | Chairman Founder | |
| ADVERUM BIOTECHNOLOGIES, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| EPIZYME, INC. | Biotechnology | Chairman General Counsel | |
| AKOUOS | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Director/Board Member Chairman | |
| TERNS PHARMACEUTICALS, INC. | Biotechnology | Chairman Chief Executive Officer | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member Chairman | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Chairman | |
| AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel | |
Diatide, Inc.
 Diatide, Inc. Pharmaceuticals: GenericHealth Technology Diatide, Inc. is a company based in Londonderry, NH. Diatide, Inc. was founded by André L. Lamotte. | Pharmaceuticals: Generic | Corporate Officer/Principal | |
Mallinckrodt Medical, Inc.
 Mallinckrodt Medical, Inc. Medical SpecialtiesHealth Technology Mallinckrodt Medical, Inc. manufactures and markets healthcare products. Its products include contrast media & delivery systems, radiology imaging products, radiopharmaceuticals and urology imaging systems. The company is headquartered in Pointe-Claire, Canada. | Medical Specialties | Corporate Officer/Principal | |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Biotechnology | Director/Board Member | |
| Berlex Laboratories, Inc. | General Counsel | ||
| VERTEX PHARMACEUTICALS INCORPORATED | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of California San Diego | College/University | Doctorate Degree | |
| GlaxoSmithKline (Pharmaceutical Operations) | Corporate Officer/Principal | ||
| University of Cambridge | College/University | Doctorate Degree | |
T-Cure Bioscience, Inc.
 T-Cure Bioscience, Inc. BiotechnologyHealth Technology T-Cure Bioscience, Inc. is an innovative immuno-oncology company based in Sherman Oaks, CA. The private company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1, and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. The CEO of the company is Gang Zeng. | Biotechnology | Director/Board Member | |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Purespring Therapeutics Ltd. provides biotechnological research and experimental development services. The company was founded on April 1, 2020 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
| PEPGEN INC. | Biotechnology | Chief Executive Officer | |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Chief Executive Officer | |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Founder | |
Pepgen Ltd.
 Pepgen Ltd. Packaged SoftwareTechnology Services Pepgen Ltd. engages in research and experimental development on biotechnology. The company was founded on January 25, 2018 and is headquartered in Oxford, the United Kingdom. | Packaged Software | Chief Executive Officer | |
The Friedreich's Ataxia Research Alliance
 The Friedreich's Ataxia Research Alliance Information Technology ServicesTechnology Services The Friedreich's Ataxia Research Alliance provides patient registry services. The private company is based in Downingtown, PA. | Information Technology Services | Director/Board Member | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| FREELINE THERAPEUTICS HOLDINGS PLC | Biotechnology | Chairman | |
| McGill University | College/University | Doctorate Degree | |
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Biotechnology | Founder | |
| Forcefield Therapeutics Ltd. | Chairman | ||
| Syncona Ip Holdco Ltd. | Director/Board Member | ||
Voisin Consulting, Inc.
 Voisin Consulting, Inc. Miscellaneous Commercial ServicesCommercial Services Voisin Consulting, Inc. provides product development consulting services. It guides biotechnology, pharmaceutical and medical technology manufacturers throughout product development and commercialization. The company was founded by Emanuelle M. Viosin in 1997 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Eliem Therapeutics (UK) Ltd.
 Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Founded in 2019, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Part of Eliem Therapeutics, Inc., the company is based in Altrincham, UK. | Biotechnology | Director/Board Member | |
| AURA BIOSCIENCES, INC. | Biotechnology | Chief Operating Officer | |
| Gettysburg College | College/University | Undergraduate Degree |
Statistics
International
| United States | 32 |
| United Kingdom | 18 |
| Canada | 3 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 5 |
| Finance | 3 |
| Commercial Services | 3 |
| Technology Services | 3 |
Operational
| Director/Board Member | 100 |
| Corporate Officer/Principal | 37 |
| Independent Dir/Board Member | 31 |
| Chairman | 26 |
| Chief Tech/Sci/R&D Officer | 14 |
Most connected contacts
| Insiders | |
|---|---|
| David Mott | 45 |
| David Lubner | 19 |
| Chris Hollowood | 18 |
| Scott Whitcup | 18 |
| David Fellows | 16 |
| James McArthur | 15 |
| Mark de Rosch | 12 |
| Trevor Anthony Mill | 10 |
| Rabia Ozden | 9 |
| Paula Cobb | 8 |
| Senthil Sundaram | 7 |
| Johanna Friedl-Naderer | 7 |
| Gregory Robinson | 6 |
| Samantha Prout | 5 |
| Valerie Morisset | 5 |
- Stock Market
- Insiders
- Steven John Green
- Company connections
